Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Short-term Investments: 2021-2024

Historic Short-term Investments for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $99.1 million.

  • Amylyx Pharmaceuticals' Short-term Investments fell 26.91% to $118.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $118.8 million, marking a year-over-year decrease of 26.91%. This contributed to the annual value of $99.1 million for FY2024, which is 50.73% down from last year.
  • According to the latest figures from FY2024, Amylyx Pharmaceuticals' Short-term Investments is $99.1 million, which was down 50.73% from $201.2 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Short-term Investments ranged from a high of $284.4 million in FY2022 and a low of $45.9 million during FY2021.
  • In the last 3 years, Amylyx Pharmaceuticals' Short-term Investments had a median value of $201.2 million in 2023 and averaged $194.9 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Short-term Investments soared by 519.28% in 2022 and then crashed by 50.73% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Short-term Investments (Yearly) stood at $45.9 million in 2021, then skyrocketed by 519.28% to $284.4 million in 2022, then dropped by 29.27% to $201.2 million in 2023, then slumped by 50.73% to $99.1 million in 2024.